Lyra Therapeutics Revenue and Competitors

Boston, MA USA

Location

#8526

Growjo Ranking

Pharma

Industry

Estimated Revenue & Valuation

  • Lyra Therapeutics's estimated annual revenue is currently $23.5M per year.(i)
  • Lyra Therapeutics's estimated revenue per employee is $201,000

Employee Data

  • Lyra Therapeutics has 117 Employees.(i)
  • Lyra Therapeutics grew their employee count by 52% last year.

Lyra Therapeutics's People

NameTitleEmail/Phone
1
Associate VP, Clinical OperationsReveal Email/Phone
2
Associate VP FinanceReveal Email/Phone
3
VP, Research And DevelopmentReveal Email/Phone
4
VP BiometricsReveal Email/Phone
5
Associate VP Analytical DevelopmentReveal Email/Phone
6
SVP, QualityReveal Email/Phone
7
VP ManufacturingReveal Email/Phone
8
SVP, Regulatory AffairsReveal Email/Phone
9
VP CMCReveal Email/Phone
10
VP, People OperationsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$413.3M3240%$634MN/A
#2
$47.8M2380%N/AN/A
#3
$2.4M12-52%N/AN/A
#4
$25.7M12839%N/AN/A
#5
$12.9M64129%N/AN/A
#6
$23.9M1198%$113MN/A
#7
$0.3M30%N/AN/A
#8
$10.3M51-14%N/AN/A
#9
$1.8M367-4%$538MN/A
#10
$50M2493%N/AN/A
Add Company

What Is Lyra Therapeutics?

Creating precisely tuned medicines so patients can breathe freely, we are pioneering a new therapeutic approach to treat debilitating ear, nose and throat diseases that impact the lives of millions of people. Lyra Therapeutics is a clinical-stage company pioneering a new therapeutic approach to treat debilitating ear, nose and throat (ENT) diseases that impact the lives of millions of people. Our goal is to transform the ENT treatment paradigm by providing effective front-line solutions for physicians and new treatment options for their patients. Lyra?s transmucosal therapeutic system, now being evaluated in a clinical study, directly targets tissues that are difficult or impossible to access with existing therapies. Building on expertise in materials science, drug development and formulation, the Lyra team has developed a proprietary platform that enables sustained, local delivery of medications over an extended period of time. Based on clinical results, this new therapeutic approach has the potential to provide significantly improved patient outcomes beyond the limited treatment and surgical options currently available for ENT diseases. Headquartered in the Boston area, Lyra Therapeutics was founded by George Whitesides and Robert Langer, academic luminaries in the fields of chemistry, materials science and biotechnology, and is backed by leading life science investors. Reach us at contactus@lyratx.com

keywords:N/A

N/A

Total Funding

117

Number of Employees

$23.5M

Revenue (est)

52%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Lyra Therapeutics News

2022-04-20 - Lyra Therapeutics, Inc. (NASDAQ:LYRA) Short Interest Up ...

Lyra Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and...

2022-04-17 - Lyra Therapeutics Announces First Patient Treated in Phase 2 ...

Lyra Therapeutics Announces First Patient Treated in Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients.

2022-04-13 - Lyra Therapeutics Announces Two Presentations at ...

WATERTOWN, Mass., April 21, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging...

2020-02-03 - Lyra Therapeutics Closes $30M Series C Financing

Lyra Therapeutics, Inc., a Watertown, Mass.-based clinical-stage therapeutics company, completed a $30m Series C financing. The round was led by Perceptive Advisors with participation from Clifton Capital as well as participation by existing investors RA Capital Management, Soleus Capital, Arro ...

2020-01-29 - Lyra Therapeutics Completes $30 Million Series C

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics, Inc., a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases, today announced it has co ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$15M119-37%$217.5M
#2
$25.2M1206%N/A
#3
$32.9M12279%N/A
#4
$33.8M125-9%N/A
#5
$22.5M1257%N/A